Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia

Supportive Care in Cancer

Volumn 21, Issue 8, 2013, Pages 2351-2357

  Al Barrak, Jasem ^a   Cheung, Winson Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adherence; Chronic myeloid leukemia; CML; Gastrointestinal stromal tumor; GIST; Imatinib

Indexed keywords

IMATINIB; PLACEBO;

ARTHRALGIA; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERPERSONAL COMMUNICATION; MEDICATION COMPLIANCE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SELF REPORT;

EID: 84879954674     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1831-6     Document Type: Review

References (37)

1. Bhattacharya D, Easthall C, Willoughby KA et al (2012) Capecitabine non-adherence: exploration of magnitude, nature, and contributing factors. J Oncol Pharm Pract 18:333-342
2. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128
3. Hohneker J, Shah-Mehta S, Brandt PS (2011) Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 7:65-67
4. Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736
5. Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388
6. McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768
7. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66
8. Weingart SN, Brown E, Bach PB et al (2008) NCCN task force report: oral chemotherapy. J Natl Compr Cancer Netw 6(suppl 3):S1-S14
9. O'Brien SG, Guilhot F, Larson RA et al (2003) For the IRIS investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004
10. Druker BJ, Guilhot F, O'Brien SG et al (2006) For the IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
11. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 8(suppl 2):S1-S41, quiz S42-S44
12. Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107-1113
13. Le Cesne A, Ray-Coquard I, Bui BN et al (2010) For the French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942-949
14. von Mehren M, Heinrich MC, Joensuu H et al. (2011) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT + gastrointestinal stromal tumors (GIST). J Clin Oncol 29(15 suppl): Abstract 10016
15. Blay JY, von Mehren M, Blackstein ME (2010) Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 116:5126-5137
16. Dematteo RP, Ballman KV, Antonescu CR et al (2009) On behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104
17. Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265-1272
18. (R). Available at http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed 21 Sep 2012
19. Noens L, van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401-5411
20. Halpern R, Barghout V, Zarotsky V et al (2009) Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 16:215-223
21. Ganesan P, Sagar TG, Dubashi B et al (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471-474
22. Yoshida C, Komeno T, Hori M et al (2011) Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol 93:618-623
23. Wu EQ, Johnson S, Beaulieu N et al (2010) Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26:61-69
24. Ray-Coquard IL, Bin Bui N, Adenis A (2010) et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol 28(15 suppl): Abstract 10032
25. Mazzeo F, Duck L, Joosens E et al (2011) Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 31:1407-1409
26. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 24(18S suppl): Abstract 6119
27. Feng W, Henk H, Thomas S et al. (2006) Compliance and persistency with imatinib. J Clin Oncol 24(18S suppl): Abstract 6038
28. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497
29. von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37:291-299
30. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632
31. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
32. Eliasson L, Clifford S, Barber N et al (2011) Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626-630
33. JÓnsson S, Olsson B, SÓderberg J et al (2012) Good adherence to imatinib therapy among patients with chronic myeloid leukemia - a single-center observational study. Ann Hematol 91:679-685
34. Regnier Denois V, Poirson J, Nourissat A et al (2011) Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl) 20:520-527
35. O'Brien SG, Guilhot F, Goldman JM et al. (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 112: Abstract 186
36. Baker LH, Rankin CJ, Blanke CD et al. (2011) Long-term follow-up of SWOG S0033, a phase III randomized intergroup trial assessing imatinib mesylate at two dose levels in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). Connective Tissue Oncology Society Annual Meeting Abstracts: Abstract 24
37. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894